Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
Status:
Recruiting
Trial end date:
2024-07-26
Target enrollment:
Participant gender:
Summary
Dinutuximab beta was designed to bind to neuroblastoma cells and other cancer cells that
express the GD2 antigen, such as STS/LMS cells, and it is believed that this binding "labels"
the cells an makes them a better target.
In addition, γδ T cells can safely be expanded in-vivo using intravenous zoledronic acid and
subcutaneous interleukin-2 (IL-2) in patients with different types of solid tumors [Dieli et
al., 2007; Pressey et al., 2016].
It is supposed that combination treatment using dinutuximab beta, zoledronic acid and IL-2 is
more effective than their use in isolation. The already-established safety profiles of these
agents make testing of the combination in GD2 positive cancers such as GD2 expressing LMS
both rational and feasible [Fisher et al., 2015].
Phase:
Phase 2
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest